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Abstract: Enhancing the coordination and quality of care for chronically ill patients is a chal-
lenge across health care systems. In Germany, following a 2002 reform, physician-based and 
patient-centered disease-management programs (DMPs) were implemented in a nationwide 
rollout. These programs are characterized by information technology support, the central role 
of a designated doctor in ambulatory care, a patient-centered approach that encourages patient 
self-management, quality assurance (including reminders and benchmarking), and financial 
incentives for physicians, patients, and sickness funds. Results of a four-year follow-up show 
that despite the programs’ implementation in a weak primary care system, quality of care and 
patient satisfaction have improved while hospitalization rates, duration of hospital stay, patient 
mortality, and drug costs have been significantly lowered. In some areas up to 90 percent of all 
eligible patients are enrolled, thereby giving the programs a broadly representative base.
                    
OVERVIEW
Disease-management programs (DMPs) were introduced into the German Statutory 
Health Insurance (SHI) in 2002, following a review by the Advisory Council for 
Concerted Action in Health Care, a think tank that directly advises the govern-
ment.1,2 In its 2000–01 recommendations, the Council had pointed to a broad 
quality chasm in the country’s prevention, diagnosis, and management of chronic 
conditions.3 As underlying causes the Council cited inadequate coordination of care, 
insufficient adherence to evidence-based treatment recommendations, neglect of pre-
vention, deficient support of patient self-management, and variations in quality of 
care. Additionally, there were no incentives for physicians, patients, or sickness funds 
in the Statutory Health Insurance (the nonprofit institutions that provide health 
insurance in Germany) to invest in chronic care.
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Most of these problems were inherent to the 
German health care system at the time. Inadequate coor-
dination of care arose from the strict segregation of care 
into ambulatory and inpatient sectors. Fragmentation 
of care was further exacerbated by a weak primary care 
system in which specialists in private practice domi-
nated general practitioners (GPs) both in number and 
income, patient information did not flow timely enough 
between providers through electronic health records, 
hospital physicians had few outpatient-care privileges, 
and the traditional lack of interprofessional cooperation 
between physicians, nurses, and social care providers had 
led to discontinuity of services. Insufficient adherence to 
evidence-based treatment recommendations was fostered 
by individual physicians working in small practices with 
few quality-management requirements and by reimburse-
ments not being tied to outcomes. Deficient support of 
patient self-management was the result of meager reim-
bursement of patient-education efforts and a paternalistic 
approach to the patient–physician relationship. Variations 
in quality of care were common because not very many 
evidence-based guidelines were accepted both by GPs and 
specialists. Neglect of prevention mainly resulted from 
a lack of adequate reimbursement for this approach and 
from insufficient patient activation.
Context: The German Health Care System
As in the United States, German primary care physicians 
operate mainly in small private practices and are paid fee-
for-service with varying degrees of bundling. Gatekeeping 
is optional but is incentivized through cost-sharing 
arrangements, and often by sickness funds (SFs). Roughly 
half of the country’s hospitals are publicly owned and half 
privately owned. Hospital doctors are generally salaried 
and not allowed to treat outpatients except under special 
circumstances. For several chronic conditions, a set of 
DMPs, guided by national evidence-based recommenda-
tions, has been introduced; these programs are imple-
mented by SFs through contracts with providers.4
To fully appreciate the process of implementation 
of the DMPs, it should be noted that the German SHI 
is a competitive social health-insurance mechanism with 
a risk-compensation system in place that provides a level 
playing field for competition between the SFs.5,6 The 
SHI covers around 90 percent of the population. In 2011 
potential members are free to choose between some 156 
SFs that are privately operated but federally regulated 
with defined legal responsibilities.7 The basic benefits 
package offered is broad and universal. What is covered is 
decided by the Federal Joint Committee, which includes 
representatives of the physician, hospital, and dental asso-
ciations as well as of the SFs and patient advocacy groups.
The SHI is financed through tax revenues, and 
contributions are shared between employers and employ-
ees, who usually have job-related insurance. However, 
contrary to the custom in the United States, employ-
ers do not generally negotiate special packages for their 
employees or contract with a particular SF. Instead, 
employees are free to choose an SF based on the services 
offered. Nonworking spouses and children are covered 
free of charge. For the unemployed, contributions are 
paid by national unemployment insurance. For pension-
ers, the employers’ share of the premium is covered by 
the pension fund.
While the Federal Ministry of Health establishes 
the legal framework of the German SHI, the Federal 
Joint Committee fills in the framework by issuing law-
like decrees and forming contracts and agreements 
among stakeholders. The Committee also has wide 
regulatory authority and can issue directives regarding 
DMPs that are binding for physicians, hospital sickness 
funds, and patients; the Committee also determines the 
diseases for which DMPs should be set up. Forerunners 
of the DMPs can be seen in small, regional programs that 
aimed at improving quality of care for the chronically 
ill through a structured approach. Evaluations of these 
small, regional pilots documented improvements in care. 
However, they never spread nationally, as they were tai-
lored to regional needs.
Along with the implementation of DMPs in the 
SHI, several measures were taken to strengthen patients’ 
rights and activation and to implement a quality-
improvement agenda, including transparency of out-
comes and quality of care within the system. For exam-
ple, patients in the programs receive printed information 
regarding diabetes, its complications, treatment options, 
and management strategies.
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The Central Research Institute of Ambulatory 
Health Care in Germany annually provides the SHI and 
the KV North Rhine and the KV Westphalia with a qual-
ity record of the DMPs in North Rhine and Westphalia, 
respectively. The Institute has also been charged to 
provide a recall system for doctors participating in the 
DMPs in North Rhine to indicate those patients who 
should be reviewed during the quarter. Biannually the 
doctors receive feedback reports that include the results 
of treating their own patients and a benchmark based 
on their regional colleagues’ results. Another element of 
these feedback reports is a continuing-medical-education 
measure consisting of an additional brief concerning a 
specific topic with relevance to the DMPs and evidence-
based guidelines.
The Issue: The Challenge of Chronic Care
Management of chronic conditions is a major challenge 
for health care systems around the world.8,9 In its Global 
Burden of Disease report, the World Health Organization 
ranks chronic diagnoses such as depression, chronic 
obstructive pulmonary disease (COPD), diabetes, and 
asthma among the top 10 causes of years lived with 
disabilities. It is projected that in 2025 an estimated 
300 million people worldwide will suffer from diabetes 
alone.10
As the prevalence of chronic conditions grows, 
so do the costs of providing adequate health care to 
the affected patients. For example, of the 18 million 
Americans suffering from diabetes in 2002, an esti-
mated 12,000 to 24,000 became blind in the next year, 
43,000 needed to start on dialysis, and 82,000 had 
a lower extremity amputated because of the disease. 
Corresponding direct and indirect costs reached $132 
billion.11 The Milken Institute projects that reasonable 
improvements in prevention and management of chronic 
disease could avert some 40 million U.S. cases over the 
next 20 years. This would translate into savings of more 
than $1.1 billion in 2023, equal to obviating 27 percent 
of the expected costs.12
Similarly, in Germany an estimated 4 million 
patients (5 percent of the total population) suffer from 
diabetes, according to data from the 1998 National 
Health Survey. New data from a telephone-based survey 
called “Health in Germany”13 give a prevalence of 7.3 
percent for self-reported diabetes among adults during 
any given year and a lifetime prevalence of 8.8 percent. 
Not surprisingly, in 2001 about 6.8 percent of all health 
care expenditures involved diabetes.14
The two most important challenges in achieving 
reasonable improvement in chronic care and prevention 
are 1) adequate management of the disease, including 
prevention, evidence-based treatment standards, and 
patient self-management; and 2) coordination of care 
across health care providers. To attain these goals, health 
care systems worldwide have embraced many different 
models of disease-management programs, which are as 
diverse as the systems themselves. Despite their diversity, 
however, the programs have demonstrated the potential 
to increase quality of care as well as patient satisfaction 
with care.15,16,17,18,19,20,21,22
Objectives of the German Disease-
Management Programs
Based on these challenges and the recommendations of 
the Advisory Board for Concerted Action in Health Care, 
the Ministry of Health prepared a bill, which was passed 
in December 2001, to implement a national rollout of 
DMPs in Germany’s Statutory Health Insurance. The 
law clearly states that the main objectives of the programs 
are to “improve coordination and enhance quality of care 
for the chronically ill.”23 The Ministry of Health further 
states that it expects the programs to “facilitate patient 
empowerment.”24
The law also stipulates that DMPs may be set up 
for diseases that fulfill the following criteria:
•	 illness is highly prevalent;
•	 quality of care could be increased;
•	 evidence-based guidelines are available;
•	 care coordination is needed across sectors and 
health care providers;
•	 disease course is improvable through patient self-
management; and
•	 treatment costs are high.
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All sickness funds in the SHI could offer the pro-
grams. Actually, the financial incentives are so strong that 
no SF could afford not to offer them.
About the Programs
The rollout of the DMPs started in early 2003, and in 
2010 more than 5.7 million insured were enrolled in 
over 11,000 programs featuring the following diagnoses: 
diabetes type 1, diabetes type 2, breast cancer, coronary 
heart disease (CHD), chronic heart failure, asthma, 
and COPD. SFs are free to design their own programs. 
However, they must adhere to certain requirements that 
are clearly stated in the law. These obligations include:
•	 definition of enrollment criteria and enrollment 
process;
•	 treatment according to evidence-based care recom-
mendations or to best available evidence;
•	 quality assurance (e.g., feedback to physicians, 
patient reminders for preventive care, and peer 
review);
•	 physician and patient education;
•	 documentation in an electronic medical record; 
and
•	 evaluation.
Although the programs may be set up by the 
SFs themselves, they must be accredited by the Federal 
Agency for Insurance in a comprehensive process.25 
Recertification is required every three years.
Target Population
The programs seek to enroll all patients diagnosed with 
the relevant disease, and at an early stage. Enrollment cri-
teria are detailed in amendments to the law. In addition 
to criteria that are medical in nature, physicians are asked 
to consider whether the patient a) could benefit from the 
therapeutic targets of the program and its strong focus 
on secondary prevention, b) is willing to participate in 
managing his or her own disease, and c) if the patient’s 
quality of life may be improved through program par-
ticipation. While these criteria led in the beginning to 
the enrollment of comparatively well-managed diabetic 
patients, before long the majority of local diabetes 
patients were involved. In the region of North Rhine, 
for example, around 80 percent to 90 percent of patients 
with diabetes are now enrolled in the programs.26
One of the reasons for this success is the potential 
for financial incentives—whether directed to patients or 
physicians—embodied in the law. For patients, copay-
ments for office visits can be waived if they enroll in the 
programs. Physicians are paid a documentation fee for 
enrolling patients and for documenting certain param-
eters. Additionally, they can be paid extra for patient edu-
cation, counseling sessions, and referrals to specialists.
Program Development and 
Implementation
The most important steps in implementing the programs 
were operationalizing the medical and legal program 
requirements of the law, and gaining physicians’ accep-
tance of the programs.27 For these tasks, the Ministry of 
Health charged a federal joint committee with forming 
disease-specific working committees to draft program 
requirements based on evidence-based recommendations. 
These committees included experts from insurers, hospi-
tal associations, universities, and boards of the different 
medical associations. A DMP working committee then 
had responsibility to synthesize the technical experts’ rec-
ommendations (Exhibit 1).
The final recommendations of the working com-
mittee were adopted by the Ministry of Health through 
legal decrees that now serve as the compulsory basis 
for contracts between providers and SFs. Thus the pro-
grams are relatively uniform in their core elements. They 
may differ, however, in their types of feedback reports, 
remuneration, incentives, and program services (such as 
patient hotlines, patient-education programs, or measures 
to ensure better access to after-hours care).
Engaging the Clinicians
Involving clinicians in care programs based on evidence-
based guidelines is not always easy, as some may view 
such participation as limiting their professionalism and 
contributing to so-called cookbook medicine. Thus, 
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physicians have to be engaged on several levels. On a 
national level, the National Association of Physicians 
(Bundesärztekammer), the National Association of SHI 
Physicians, and the consortium of German Scientific 
Medical Associations (AWMF) were charged with draw-
ing up “national management guidelines” (Nationale 
Versorgungsleitlinien) for enrolled patients. The guide-
line-forming methodology, overseen by the Agency for 
Quality in Medicine (ÄZQ), is a consensus process based 
on national and international literature on evidence-
based medicine. There now are different versions of these 
guidelines—a long version for experts (physicians) and 
short versions that are essentially algorithms for routine 
use by patients. The Institute for Quality and Efficiency 
in Health Care (IQWiG) is charged with regularly check-
ing recommendations in the programs against interna-
tional norms.
On the individual physician level, participation 
in the DMPs is voluntary. However, there is a financial 
incentive: physicians receive various fees for DMP-
associated services. Consider, for example, patient educa-
tion. For teaching a group class the physician is reim-
bursed at €60 per patient for a 60-minute session. For 
the care of each diabetes patient the physician receives a 
lump-sum payment of €15 per quarter in addition to the 
regular reimbursement. For referral of a patient to a dia-
betes specialist he or she receives €5.11 per case. Besides 
these and other financial incentives, physicians earn 
credits for continuing medical education when they take 
a training class on the details of the DMP contracts, their 
new responsibilities, and care goals, among other topics. 
Such training, offered once a year, is mandatory for pro-
gram participants.
Exhibit 1. Flow Chart for Determining Program Requirements
Source: Authors’ illustration.
Ministry of Health
Joint committee of self-governing bodies
Representatives from sickness funds,
hospital association, physicians’ association,
dentists’ association
Disease-specic working committee
(includes experts from universities,
associations, or boards)
Working committee DMP
Legal supervision
Forms
Nominates
Issues legal 
decrees as
basis for
contracts
Synthesizes 
the evidence
Drafts nal 
proposal for 
lawmaking 
process
Proposes disease-
specic program 
requirements 
based on 
evidence-based 
guidelines
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How the Programs Work
Core components of the programs. The core DMP elements 
are listed in Exhibit 2 and include treatment recom-
mendations based on evidence-based guidelines, the use 
of information technology (IT) to manage disease, the 
DMP physician as coordinator and navigator of care, 
tracking and reporting of process and outcome, support 
of shared decision-making and patient training in manag-
ing their own disease, and a focus on prevention.
With these core components, the DMPs represent 
a major departure from traditional care. Patient activa-
tion, treatment according to evidence-based guidelines, 
the systematic use of IT for documentation, evaluation, 
and quality assurance—all of which were applied sporadi-
cally in the past—are now exercised systematically and 
comprehensively throughout the German health care 
system.
Physicians in primary care play a central role. GPs, 
family doctors, specialists, and hospitalists cooperate 
closely in the DMPs to care for patients. However, only 
GPs and family doctors may apply to become a “DMP 
doctor” (with the exception of gynecologists in DMPs 
for breast cancer). As such, primary care physicians play 
a central role in coordinating and ensuring timely access 
to care. They harmonize care across health care and social 
care providers, educate and advise patients on self-man-
agement of disease and utilization of services, negotiate 
individual treatment goals with patients, and document 
the degree of achievement of care targets. Thus, the role 
of a DMP doctor in many aspects resembles what is cur-
rently called for in the concept of a “medical home.”
In addition, DMP doctors ensure treatment in 
accordance with evidence-based care guidelines, adhere 
to programs’ referral rules and follow their documenta-
tion routines, play an active role in quality-improvement 
networks, and participate regularly in continuing medical 
education. DMP doctors may also be required to meet 
certain service standards—e.g., a maximum of 30 min-
utes waiting time for patients, or evening office hours 
to accommodate working patients. Beyond encourag-
ing physicians to participate in DMPs in the first place, 
financial incentives are used to ensure that their practices 
are in accordance with program expectations.
Role of nurses and teams in DMP primary care 
practices. Implementation of the DMPs has facilitated the 
involvement of nurses—and of other “physician assis-
tants,” as they are called in Germany. Further training of 
physician assistants has been boosted through the DMPs 
because services such as education are now better reim-
bursed. Also, the programs’ characteristic cooperation of 
physicians with other medical professionals—e.g., dieti-
cians, podiatrists—has been groundbreaking in that these 
individuals have for the first time become fully integrated 
into primary care practices. Thus, DMP doctors may 
now delegate specific tasks to trained physician assistants 
or other professionals.
Programs aim to activate patients. The DMPs 
emphasize patient education, individualized patient care, 
and shared decision-making. Based on national care 
targets, physicians negotiate individual treatment goals 
and plans with patients;28 and all patients are required to 
participate regularly in training programs. Another hall-
mark of the DMPs is that physicians take time to explain 
to patients why certain tests or referrals—for example, 
a yearly checkup at the ophthalmologist’s office—are 
evidence-based and necessary. SFs may create strong 
financial incentives, such as the waiving of copayments, 
for patients to enroll in the programs.
Quality assurance in the programs is extensive. In 
order to ensure that the targeted improvements in qual-
ity of care are achieved, DMP physicians and their office 
staff must meet certain quality standards with respect to 
education, advanced training, IT use, and availability 
of services. National care goals are operationalized into 
benchmarking algorithms. Feedback reports, designed to 
support physicians in reaching care goals, allow the cross-
sectional and longitudinal analysis of individual patients 
as well as the analysis of outcomes on an aggregated 
level. The reports also generally include a benchmark of 
regional colleagues’ results against which the individual 
physician can compare his or her own practice’s out-
comes. To ensure comparability, the feedback provided is 
routinely “controlled” for the level of patient complexity 
or severity, and practice anomalies, such as a higher aver-
age age of patients, are pointed out.
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Exhibit 2. Core Components of German DMPs
Component Description
Evidence-based guidelines Provide a mandatory basis for national care goals, treatment recommendations, 
physician- and patient-education requirements, quality-improvement networks, physician 
performance feedback, and reminders for follow-up and preventive care.
Use of information-
technology systems
Electronic medical records are required to: routinely document a national set of 
indicators; create a patient registry; enable the individual physician to track and 
monitor chronically ill patients with respect to outcomes and process parameters; 
and support evaluation, feedback, benchmarking, and the generation of reminders for 
physicians and patients.
Physician-based The programs are mainly under the responsibility of primary care physicians. They 
enroll and educate patients, negotiate individual treatment goals, and coordinate care. 
Physicians may delegate these tasks to trained office staff who operate under the 
physician’s supervision. 
Quality improvement, 
reporting, and tracking
Quality assurance includes individual physician feedback and biannual benchmark 
reports that compare each practitioner’s performance to that of a peer group. Individual 
physician reminders—e.g., for referring patients to screening for retinopathy—are sent 
every three months when appropriate; patient reminders are automatically generated 
every three months for follow-up care and preventive care. Physicians must also 
participate in quality-improvement circles, where patient cases are presented and 
medical treatment options are discussed among peers. 
Patient activation Individualized care plans and care goals are negotiated between physicians and 
patients. Patient activation is also supported by patient education, which is provided 
directly by the physician and qualified nurses, by information contained in brochures, 
and by sickness funds’ hotlines. 
Population-based and 
prevention-oriented
Approximately 90 percent of the population (i.e., all statutory health insured) have 
access to DMPs if they are eligible. Programs are uniform with respect to quality 
standards, national care goals, evidence-based treatment recommendations, evaluation 
requirements, and quality-assurance measures, though programs may differ in their 
service aspects. Overall, the focus of the programs is on secondary prevention. All 
patients are encouraged to enroll in this no-high-risk approach. 
Financial incentives There are financial incentives for sickness funds, physicians, and patients. Sickness 
funds now receive a lump-sum payment of US$224 as administration fee for each 
enrolled patient. Physicians receive a documentation fee of about $33 for the first 
documentation and $13 per quarter thereafter. For enrolled patients, copayments are 
waived. This benefit can amount to a substantial sum, as copayments are otherwise 
required of the chronically ill for medication (up to $13 per prescription) and for 
hospital use and physical therapy (up to 1 percent of gross income). 
Every six months the feedback reports include a 
specialized subgroup analysis on a specific topic. Results 
of this analysis are interpreted in the report and com-
bined with topic-relevant physician-education material 
that is certified as part of continuing medical education. 
To ensure that feedback reports are tailored to physicians’ 
needs, annual surveys are conducted. Additionally, 
quality circles (QCs) are held regularly so that doctors 
will have the opportunity to discuss individual cases 
and receive peer feedback in a protected environment. 
Feedback reports or specially prepared quality reports 
may be used as the basis for discussions in QCs.
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Incentives. Acceptance of the DMPs is due at least 
in part to the various financial incentives that were cre-
ated.29,30 For physicians, financial incentives include 
reimbursement for documentation, patient education, 
and coordination of care; a nonmonetary incentive is 
that physicians benefit from the high patient satisfaction 
in the programs. Patients are incentivized with financial 
bonuses (such as the waiving of copayments), with the 
assurance that they will receive personalized and evi-
dence-based care, and with improvements in services and 
more patient-centered care.
For SFs, financial incentives include a lump-sum 
administration-fee payment of about €168 (US$224) 
per enrolled insured. This payment comes from the Risk 
Compensation Scheme (RCS), which was set up to pro-
vide a level playing field for competition between SFs. 
It compensates for differences in morbidity and income 
between funds that are due to historical reasons; that is, 
prior to 1996, workers could only join designated funds. 
Certain regional SFs, for example, insured only blue-
collar workers, who on average had higher morbidity and 
lower incomes than the insured of the SFs that enrolled 
only white-collar workers. The RCS was implemented to 
render such differences in the insured-population struc-
ture essentially immaterial.
Examples of Three Large Programs
ELSID study (Evaluation of a Large-Scale Implementation 
of Disease-Management Programs). The ELSID trial was 
the evaluation of the DMP for Diabetes Mellitus Type 
2 of the AOK (Allgemeine Ortskrankenkasse) sickness 
funds in the regions of Rhineland Palatinate (around  
1 million insured) and Saxony-Anhalt (750,000 insured). 
In a prospective cluster-randomized comparison, two 
intervention groups were compared with a control 
group in routine care.31 Intervention Group 1 consisted 
of a regular DMP group as described in this paper. 
Intervention Group 2 was made up of patients enrolled 
in regular DMPs but who receive additional interven-
tions such as outreach visits (outcomes of this group 
will not be reported in this paper). Two hundred DMP 
physicians, with each doctor enrolling 20 patients, were 
recruited for the study.
For the analysis, routine DMP documentation 
data were provided by the AOK SFs in the two German 
states, and an intention-to-treat analysis approach was 
taken to evaluate these data.32 Altogether more than 
20,000 insured (with an average age of 70.7 years) in 
519 practices were followed over a three-year period. 
Preliminary results have been published. Additionally, in 
the ELSID trial all AOKs conducted longitudinal analy-
sis of the routine documentation data. These analyses 
included medical data such as blood pressure, HbA1c-
values, and smoking status.
DMP program of the BARMER sickness fund. The 
effectiveness of the BARMER SF’s nationwide DMP for 
diabetes mellitus type 2, compared with routine care, was 
evaluated in a retrospective propensity score-matched 
approach over a four-year period (2003–2007). The 
BARMER (now BARMER GEK) is the single largest 
sickness fund in the SHI. It covers some 10.4 percent of 
the population and operates across Germany. From the 
initially identified 234,262 insured, 19,882 matched 
pairs could be formed. Propensity scores were estimated 
using a stepwise logistic regression. Variables for match-
ing included disease severity and socioeconomic variables.
Preliminary results, including prior matched-pair 
analysis and patient surveys, have been published. In 
2007 a matched-pair analysis of 221,780 insured was 
carried out; it compared an intervention group (enrolled 
in DMPs) with controls in regular care in a retrospec-
tive analysis of SF utilization data. Based on the four 
years of data, overall mortality was significantly lower 
for in-program patients. Overall drug and hospital costs, 
average duration of hospital stay, and average number of 
hospitalizations also were lower for patients enrolled in 
the program.33
Evaluation of the DMP for diabetes mellitus type 2 
in the region of North Rhine. The evaluation is carried out 
annually by the Joint Institution DMP in North Rhine 
(Nordrheinische Gemeinsame Einrichtung Disease-
Management Programme GbR) and published in the 
form of a report.34 In 2009 a total of 423,518, or 79 per-
cent of all insured diabetics, were enrolled in the North 
Rhine region’s DMP for diabetes mellitus type 2. At the 
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same time, more than 88 percent of all GPs/family doc-
tors in the area were listed as “DMP physicians.”
In contrast to the two above-mentioned studies 
(ELSID and the BARMER DMP), the evaluation in 
North Rhine is based not on SF data but rather on data 
from a consortium of sickness funds and the association 
of ambulatory care physicians (KV). Therefore medical-
outcome data such as HbA1c, blood-pressure control, 
cholesterol level, or the results of regular checkups with 
an ophthalmologist can be included in the analysis. The 
mean age of the enrolled diabetes patients in 2009 was 
67.5 years, with an average disease duration of 9.4 years.
Program Outcomes
Medical outcomes. Preliminary results of the programs are 
encouraging.35,36,37,38 While the data reported from the 
various programs reflect different evaluation designs, all 
evaluation results show improvements in medical out-
comes. The ELSID study reported a significant reduction 
in mortality in favor of Intervention Group 1 (DMP 
group without further interventions), with a mortality 
rate of 9.5 percent compared with 12.3 percent in the 
control group.39 This means that the average insured 
enrolled in a DMP had a 1.3-times higher chance to 
survive the two-and-a-half years of the evaluation period 
compared with patients of the control group. After 
adjustment for age, comorbidities, and other variables, 
the difference was still statistically significant.
Similar results are reported in the DMP for coro-
nary artery disease.40 In addition, changes in lifestyle, 
such as to stop smoking, are described in the routine doc-
umentation. In the longitudinal evaluation of the AOKs 
of Rhineland and Hamburg, 23 percent to 32 percent 
and 22 percent to 28 percent, respectively, quit smoking 
in the various cohorts during the first two years of enroll-
ment in a DMP.
The BARMER sickness fund first reported medi-
cal outcomes data in 2007, when 221,780 patients were 
evaluated in a matched-pair analysis. Those enrolled 
in the DMP had fewer hospital admissions because of 
heart attack and stroke, had fewer amputations (Exhibit 
3), and their medications were more often in line with 
evidence-based recommendations.
The longitudinal analyses of the DMP of North 
Rhine support the results reported in the BARMER 
and AOK studies. Some 70,630 insured patients were 
Notes: Lower extremity = amputation below the knee; foot = amputation of whole foot or part of foot or toes; foot or leg = not 
specied.
Source: Evaluation of the BARMER Sickness Fund’s nationwide disease-management program for Diabetes Mellitus Type 2, 
2003–2007. 
Exhibit 3. Number of Patients per 1,000 Enrolled Program Participants 
Who Were Hospitalized at Least Once with the Described Diagnosis, 2006 
Patients per 1,000 insured
Lower extremity, 
male
Foot, male Foot, female Foot or leg, 
female
Foot or leg, male Lower extremity, 
female
Disease-management program
Nonparticipant
4.1
0.8
0.2
1.9
1.4 1.5
2.7
3.8
1.6
4.5
7.3
6.0
8
6
4
2
0
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followed over a four-year period regarding their HbA1c 
levels. They were grouped into four clusters, according to 
mean value of HbA1c at enrollment (Exhibit 4).
As seen in Exhibit 4, DMP patients with the high-
est HbA1c levels at enrollment demonstrated the greatest 
benefit from the programs regardless of age, sex, or dura-
tion of disease at the time. (For enrolled patients with 
low HbA1c levels at enrollment, a slight increase can 
be noted. One explanation may be that doctors have to 
essentially walk a tightrope in trying to avoid both hypo- 
and hyperglycemia.) In addition to closer management 
by their DMP doctor, other possible triggers for improve-
ments in HbA1c levels seem to be patient education and 
referral routines (Exhibit 5).
Changes similar to those in HbA1c can be 
observed in blood pressure. For elderly patients, the 
blood-pressure target values (below 140/90 mm Hg) were 
achieved by some 48 percent to 55.6 percent in 2009. 
For younger insured patients and those with a history 
of coronary artery disease, the target was set below 130 
mm Hg and achieved by almost 40 percent of enrolled 
patients younger than 56 years of age. Improvements can 
also be seen in the incidence of endpoints such as heart 
attack, stroke, amputation, blindness, and dialysis.
Because DMPs represent a patient-centered 
approach to care management, patient-centered out-
comes are also important in judging the effectiveness of 
the programs:
Patient-reported outcomes and measures of patient-
centered care experiences. In a patient survey of the AOKs 
(involving more than 1,000 enrolled diabetics, with a 
mean age of 66 years), 56 percent of the patients agreed 
that the quality of their care had improved, 95 percent 
had been referred to an ophthalmologist annually,  
88 percent had regularly had their feet inspected, 80 per-
cent had changed their eating habits since enrolling in 
the program, and only 10 percent said that their DMP 
doctor had not negotiated individual treatment goals 
with them.41 In a survey conducted by the ELSID study 
group, 63 percent of enrolled patients reported that their 
doctor had always taken time to explain to them why 
a referral to a specialist was needed and how it would 
10.0
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
Source: DMP Quality Report 2009, Joint Institution DMP of North Rhine (Nordrheinische Gemeinsame Einrichtung Disease-
Management Programme GbR).
Exhibit 4. Changes in HbA1c Levels in Enrolled Diabetes Patients, 2004–2009
HbA1c (%) Baseline
>8.5 (n=7,036)
>7.5—<8.5 (n=14,546)
>6.5—<7.5 (n=34,529)
<6.5 (n=43,156)
Enrolled 
in DMP
July—Dec 
2004
Jan—June 
2005
July—Dec 
2005
Jan—June 
2006
July—Dec 
2006
Jan—June 
2007
July—Dec 
2007
Jan—June 
2008
July—Dec 
2008
Jan—June 
2009
July—Dec 
2009
8.09
9.44
7.94
6.98
5.97
7.72
7.31
6.77
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impact the disease. In a survey using the PACIC (Patient 
Assessment of Chronic Illness Care), patients recognized 
care in the programs as being more structured than rou-
tine care.42 As an overall trend across surveys, patients in 
the DMPs tend to be more satisfied with the care they 
receive and their overall health state. Also, they feel more 
able to cope with their disease, and they perceive them-
selves to be well informed about it.
Cost outcomes. The ELSID study group reported 
fewer hospital stays for enrolled patients in comparison 
with the control group. Three AOK DMP programs for 
diabetes mellitus (Bavaria, Saxony, and Thuringia) were 
evaluated regarding costs of enrolled versus nonenrolled 
ensured. All three programs showed overall cost reduc-
tions for enrolled patients relative to the nonenrolled 
(Exhibit 6).
The BARMER DMP evaluation showed that the 
average number of hospitalizations, average duration of 
hospital stay, and overall drug and hospital costs over a 
four-year period were lower for patients enrolled in the 
program.
Lessons Learned from the German 
Disease-Management Programs
The quest to reorganize chronic care has led to a variety 
of approaches in different countries’ health care sys-
tems. Among the most notable are Germany’s disease-
management programs, which were implemented on a 
national level—with national regulation and funding—in 
2002. Today, a substantial number of diabetes patients 
are enrolled in the programs nationwide. In some areas, 
coverage of the programs includes close to 90 percent of 
all patients with diabetes and more than two-thirds of all 
primary care physicians.
These programs have had a measurable and posi-
tive impact on chronic care; enrolled patients who were 
surveyed with the PACIC instrument and the EQ-5D 
(an instrument to measure quality of life) report that 
their care has become more structured and their health-
related quality of life improved.43 Improvements were 
largest in the areas of follow-up/coordination of care, 
goal setting and tailoring, and problem-solving. Medical 
outcomes such as mortality, complication rates, and 
HbA1c levels improved in the programs.44 While quite 
a few disease-management programs in other countries 
Source: DMP Quality Report 2009, Joint Institution DMP of North Rhine (Nordrheinische Gemeinsame Einrichtung Disease-Management 
Programme GbR).
Exhibit 5. Changes in HbA1c Levels for Diabetes Patients After Specialist Referral
HbA1c (%)
Time since specialists’ referral
3–6 
months 
before
6 months 
after
12 months 
after
(n=79,649)
18 months 
after
(n=75,355)
24 months 
after 
(n=64,972)
30 months 
after
(n=58,065)
36 months 
after
(n=50,459)
42 months 
after
(n=43,543)
8.0
7.6
8.2
8.0
7.8
7.6
7.4
7.2
7.0
Start of
referral
routines
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can demonstrate such improvements in quality of care as 
well, early economic evaluations of the German programs 
also indicate cost-effectiveness,45 especially with respect 
to hospital utilization. Moreover, costly complications, 
such as amputations, strokes, and heart attacks, are being 
reduced in these programs.
Factors contributing to the success of the programs. 
Evaluation of the first years’ medical outcomes of various 
diabetes disease-management programs in the German 
SHI supports the following conclusion: A nationwide 
standardization of care according to evidence-based 
guidelines, combined with a strong emphasis on qual-
ity assurance and primary care doctors as leaders in the 
process, can lead to improved outcomes in chronic care. 
Although the programs were implemented from the top, 
they were drafted through a process that included all 
major stakeholders (except patients).
Facilitating factors in the German experience 
include:
•	 Changes to date have included, for example, the 
reduction of bureaucracy by reducing documenta-
tion requirements and the transition from paper 
to electronic forms.
•	 Thus all patients enrolled in the programs can 
be treated according to the same standards. 
Physicians do not need to switch treatment stan-
dards between patients enrolled in the programs of 
different sickness funds.
•	 For patients who opt into the programs, copay-
ments are waived; physicians receive a documenta-
tion fee for each enrolled individual per quarter; 
specialists get training programs reimbursed; and 
sickness funds receive a yearly administration fee 
for each enrollee.
•	 Other quality-assurance measures, such as qual-
ity circles in which individual cases are discussed 
with peers, are more hands-on. They are comple-
mented by national standards for referral routines. 
For example, if a general practitioner does not 
succeed in bringing a patient’s HbA1c or blood-
pressure level into the recommended range within 
six months, he or she must refer the patient to a 
specialist, who in turn must refer the patient back 
within a certain time frame and submit an exten-
sive report.
Exhibit 6. Cost Experience to Date in the DMPs for Diabetes Mellitus  
in Bavaria, Thuringia, and Saxony
Cost per insured per year, in US$ 
Cost categories AOK Bavaria AOK Plus (Thuringia) AOK Plus (Saxony)
Nonenrolled
Ambulatory care
Medication
Inpatient care
Overall cost
990
1,846
2,810
6,815
815
2,032
2,678
6,413
887
2,078
2,315
6,400
Enrolled
Ambulatory care
Medication
Inpatient care
Overall cost
1,182 (+19.32%)
1,729 (–6.41%)
2,428 (–13.59%)
6,278 (–7.87%)
883 (+7.69%)
2,038 (+0.28%)
1,965 (–36.28%)
5,581 (–14.81%)
954 (+6.96%)
2,127 (+2.33%)
1,738 (–33.14%)
5,749 (–11.31%)
Notes: €1 = US$1.3361; figures in brackets denote difference as percentage. 
Source: Modified according to AOK-Bundesverband, and I. Biesterfeld and P. Willenborg, “Chronikerprogramme lohnen sich,” Gesundheit und 
Gesellschaft, June 2009 12(6):18–19.
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Implications for policymakers. Although Germany 
traditionally has had a weak primary care system, the 
nationwide implementation of DMPs has been success-
ful. Key elements in this success include financial incen-
tives for SFs, doctors, and patients to actively engage in 
managing chronic care; a sophisticated system of elec-
tronic medical records; and a quality-assurance system. 
Of course, there are also limitations and caveats for poli-
cymakers that need to be addressed when considering the 
implementation of such programs. One is selection bias, 
which may influence medical outcomes in the programs 
and thus may affect program results. However, it is note-
worthy that in the region of North Rhine, the same med-
ical-outcome improvements as in other regions could be 
shown despite an enrollment rate of some 80 percent to 
90 percent of all diabetics. Under “real-life” conditions, 
at least, the programs show considerable improvement in 
the quality of care of chronic illnesses.
Other weak points are the insufficient integra-
tion of community resources into the programs and the 
lack of systematic decision support. Both of these ele-
ments are part of the chronic care model, but they were 
not made explicit when the programs were drafted—they 
constituted too big a task to tackle at the time. Another 
limitation is the programs’ single-disease focus, which 
should be changed to a modular approach in order to 
mirror the increasing multiple morbidities of the pre-
dominantly elderly patients. A first step in this direction 
has been the DMPs’ integration of all internal-medicine 
diagnoses into a common documentation routine with 
separate parts for individual diseases. A second step has 
been the integration of a heart-failure module into the 
DMP for coronary heart disease, thereby commencing 
that modular approach.
In reorganizing care, the programs could ben-
efit from a stronger role for trained nurses in further-
ing patient education and patient self-management of 
chronic diseases. In general, trained medical personnel 
who are nonphysicians need to be central in these pro-
grams as they move from a treatment approach to a man-
agement approach. The “guided care model”46 provides 
a good example of the integration of various tools to 
strengthen patient self-management coupled with trained 
nurses’ administration.
Implications for the United States. Although 
Germany, like the United States, traditionally has a weak 
primary care system, the disease-management programs 
for the chronically ill could be rolled out successfully in 
a national campaign. This success was due in no small 
part to the programs’ sustained funding and their rapid 
and extensive nationwide setup. Moreover, it is expected 
that regional variations in quality of care will be mini-
mized: care is standardized to evidence-based guidelines, 
and an extensive database will be used to analyze trends 
in the quality of care and to adjust program procedures 
accordingly.
These strengths of the national rollout of the 
programs are at the same time a weakness that would 
especially manifest itself in the United States, as they 
limit the programs’ regional adaptability. A statewide 
rollout might be a more pragmatic solution for the 
United States. On the other hand, U.S. discussion on 
the implementation of medical homes shows quite a 
few similarities with the German discussion around the 
disease-management programs. Requirements such as 
timely appointments or the coordination of care through 
one physician (in the DMPs, the primary care physician) 
highlight the similarities between the two approaches. In 
fact, each disease-management GP in Germany could be 
thought of as providing a medical home for each enrolled 
patient.
In retrospect, it can be said that the disease-man-
agement programs are apt to considerably enhance pri-
mary care for chronically ill patients. Our results suggest 
that intensified care and strengthened self-management 
can sustain improvement in relevant health outcomes.
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